Literature DB >> 24037659

Prevalence of human papillomavirus infection and genotype distribution determined by the cyclic-catcher melting temperature analysis in Korean medical checkup population.

Yun-Jee Kim1, Min-Jung Kwon, Hee-Yeon Woo, Soon-Young Paik.   

Abstract

Although cytology screening has reduced the incidence and mortality rate of cervical cancer significantly, its usefulness is limited to samples from the site of the lesion, resulting in its low sensitivity and unsuitability for use in medical checkups. The purpose of the present study was to evaluate the prevalence of HPV infection using genotype distribution and to analyze the correlation of the HPV DNA test results with cytological results. We also evaluated the benefits of quantitative information obtained from cyclic-catcher melting temperature analysis (CMTA) in screening for cervical cancer. We performed cyclic-CMTA using Anyplex™ II HPV28 Detection in combination with cervical cytology for 2,181 subjects. The following HPV positivity types were detected using cyclic-CMTA and HPV positivity was found to increase together with the severity of the cytology results: (1) For 419 HPV positive specimens, HPV DNA was detected in 18.1% of normal specimens, 78.3% of ASCUS, and all of LSIL and HSIL; (2) high-risk HPV DNAs were detected in 63.3% of normal (N=547), 65.9% of ASCUS (N=41), 76.9% of LSIL (N=13), and 88.9% of HSIL (N=9) among total detected HPV DNA regardless multiple detection; (3) multiple HPV genotypes were detected in 4.8% of normal specimens (N=2,146), 52.2% of ASCUS (N=23), 57.1% of LSIL (N=7), and 40.0% of HSIL (N=5). In addition, a high level of viral DNA was observed using cyclic-CMTA in all specimens beyond the LSIL stage according to cytology, while only 6% of specimens with normal cytology showed a correlation with viral quantitation by cyclic-CMTA. The combination of HPV genotyping with a quantitative assay and cytology will allow for a more accurate diagnosis of cervical cancer.

Entities:  

Mesh:

Year:  2013        PMID: 24037659     DOI: 10.1007/s12275-013-3160-3

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  22 in total

1.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

Authors:  Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers
Journal:  CA Cancer J Clin       Date:  2012-03-14       Impact factor: 508.702

2.  Prevalence of human papillomavirus infection in women in Busan, South Korea.

Authors:  Hai-Rim Shin; Duk-Hee Lee; Rolando Herrero; Jennifer S Smith; Salvatore Vaccarella; Sook-Hee Hong; Kap-Yeol Jung; Hyun-Ho Kim; Un-Dong Park; Hyung-Su Cha; Soyoon Park; Antoine Touzé; Nubia Muñoz; Peter J F Snijders; Chris J L M Meijer; Pierre Coursaget; Silvia Franceschi
Journal:  Int J Cancer       Date:  2003-01-20       Impact factor: 7.396

3.  Human papillomavirus infections with multiple types and risk of cervical neoplasia.

Authors:  Helen Trottier; Salaheddin Mahmud; Maria Cecilia Costa; João P Sobrinho; Eliane Duarte-Franco; Thomas E Rohan; Alex Ferenczy; Luisa L Villa; Eduardo L Franco
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-07       Impact factor: 4.254

4.  Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer.

Authors:  K L Wallin; F Wiklund; T Angström; F Bergman; U Stendahl; G Wadell; G Hallmans; J Dillner
Journal:  N Engl J Med       Date:  1999-11-25       Impact factor: 91.245

5.  Current status of cervical cancer and HPV infection in Korea.

Authors:  Young-Tak Kim
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

6.  Human papillomavirus (HPV) type distribution in Korean women: a meta-analysis.

Authors:  Jeong-Hoon Bae; Sung-Jong Lee; Chan-Joo Kim; Soo-Young Hur; Yong-Gyu Park; Won-Chul Lee; Young-Tak Kim; Timothy L Ng; Hans L Bock; Jong-Sup Park
Journal:  J Microbiol Biotechnol       Date:  2008-04       Impact factor: 2.351

7.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.

Authors:  G Y Ho; R D Burk; S Klein; A S Kadish; C J Chang; P Palan; J Basu; R Tachezy; R Lewis; S Romney
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

8.  Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer.

Authors:  Barbara Bachtiary; Andreas Obermair; Bettina Dreier; Peter Birner; Gerhard Breitenecker; Tomas-Hendrik Knocke; Edgar Selzer; Richard Pötter
Journal:  Int J Cancer       Date:  2002-11-20       Impact factor: 7.396

Review 9.  Human papillomavirus and cervical cancer.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

Review 10.  The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity.

Authors:  Peter J F Snijders; Adriaan J C van den Brule; Chris J L M Meijer
Journal:  J Pathol       Date:  2003-09       Impact factor: 7.996

View more
  2 in total

1.  Therapeutic potential of an AcHERV-HPV L1 DNA vaccine.

Authors:  Hee-Jung Lee; Jong Kwang Yoon; Yoonki Heo; Hansam Cho; Yeondong Cho; Yongdae Gwon; Kang Chang Kim; Jiwon Choi; Jae Sung Lee; Yu-Kyoung Oh; Young Bong Kim
Journal:  J Microbiol       Date:  2015-05-30       Impact factor: 3.422

2.  Use of swabs for dry collection of self-samples to detect human papillomavirus among Malagasy women.

Authors:  Pierre Vassilakos; Rosa Catarino; Stephanie Bougel; Maria Munoz; Caroline Benski; Ulrike Meyer-Hamme; Jeromine Jinoro; Josea Lea Heriniainasolo; Patrick Petignat
Journal:  Infect Agent Cancer       Date:  2016-03-17       Impact factor: 2.965

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.